Mauro Di Ianni1,2*†
Beatrice Del Papa3†
Stefano Baldoni4
Ambra Di Tommaso4Bianca Fabi4Emanuela Rosati5Annalisa Natale2Stella Santarone2Paola Olioso2Gabriele Papalinetti2Raffaella Giancola2Patrizia Accorsi2Paolo Di Bartolomeo2
Paolo Sportoletti3Franca Falzetti3
- 1Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy
- 2Department of Hematology, Transfusion Medicine and Biotechnologies, Ospedale Civile, Pescara, Italy
- 3Institute of Hematology-Centro di Ricerche Emato-Oncologiche (CREO), University of Perugia, Perugia, Italy
- 4Department of Life, Health and Environmental Sciences, Hematology Section, University of L’Aquila, L’Aquila, Italy
- 5Department of Experimental Medicine, Biosciences and Medical Embriology Section, University of Perugia, Perugia, Italy
In allogeneic hematopoietic stem cell transplantation, which is the major curative therapy for hematological malignancies, T cells play a key role in the development of graft-versus-host disease (GvHD). NOTCH pathway is a conserved signal transduction system that regulates T cell development and differentiation. The present review analyses the role of the NOTCH signaling as a new regulator of acute GvHD. NOTCH signaling could also represent a new therapeutic target for GvHD.
Introduction
Hematopoietic stem cell transplantation from allogeneic donors is the major curative therapy for hematological malignancies such as acute leukemias (ALs). The development of graft-versus-host disease (GvHD) is the most common complication which dramatically increases post-transplant morbidity and mortality (1). The clinical presentations of GvHD include acute GvHD (aGvHD) which regards 30–50% of transplanted patients and chronic GvHD (cGvHD) which includes 30–70% of patients who underwent allogeneic hematopoietic stem cell transplantation (2, 3). GvHD is triggered by the donor T cells that can cause an inflammatory disease ultimately leading to severe multiorgan damage (liver, gut, and skin) (4–8).
Donor T cells play a crucial role not only in mediating the onset of GvHD but also in eradicating malignancy, the graft-versus-leukemia (GvL) effect as showed by clinical (9, 10) and experimental studies (11–13). Allogeneic T cells recognize host antigens on leukemic cells and leukemia-specific responses may also occur (14). Despite this strong GvL effect exerted by donor T cells, relapse is still the major cause of treatment failure in high-risk AL patients who underwent allogeneic HSCT (15–18). Strategies to separate GvHD and GvL are then under investigation.
The NOTCH signaling pathway relies on the interactions between receptors (NOTCH1–4) and ligands (Jagged1 and -2 or Dll1, -3, and -4) that are expressed on neighboring cells (19). The interactions NOTCH/NOTCH ligand induce proteolytic activation of the receptor by an ADAM family metalloprotease and then by the γ-secretase complex. The sequential cuts lead to the release of the active intracellular NOTCH (ICN) that enters the nucleus and interacts with the DNA binding CSL/RBP-Jk factor, constituting a transcriptional activation complex with a mastermind-like (MAML) family coactivator. This ultimately promotes the transcription of target genes, controlling crucial biologic processes, such as survival, proliferation, and differentiation (20). Besides the canonical ICN/CSL/MAML-dependent transcriptional activation, RBP-Jk-independent non-canonical NOTCH signaling have also described (21, 22).
NOTCH signaling was first studied for its fundamental role in the early step of lymphopoiesis (23) and it has been implicated also in mature T cell function (24–26). More recently, NOTCH signaling has emerged as a new regulator of acute (27–32) and cGvHD (33). In this review, we will focus on NOTCH signaling and aGvHD.
NOTCH Signaling is Activated During GvHD in Donor T Cells
NOTCH and alloimmune responses have been extensively studied in GvHD and in non-GvHd models. In Severe Aplastic Anemia (SAA) mouse model, Roderick et al. (34) showed NOTCH signaling mediate Th1 cell differentiation and T-BET expression. Treatment with γ-secretase inhibitors (GSIs) reduced NOTCH and T-BET expression and rescued mice from SAA.
In the setting of GvHD, the Kean group (35) demonstrated the existence of NOTCH-related signature in alloreactive T cells harvested from a non-human primate model.
The Maillard group reported that NOTCH signaling is a strong regulator of T-cell activation, differentiation, and function during GvHD (28, 36). Murine models of allo-HCT showed that inhibition of canonical NOTCH signaling markedly decreased GVHD severity and mortality (28–30). NOTCH inhibition dramatically reduced the accumulation of alloreactive T cells in the gut. Interestingly, NOTCH-inhibited T cells significantly retained their antileukemic activity. By using humanized antibodies and conditional genetic models, Tran et al. (29) demonstrated that all the effects of NOTCH signaling during GvHD were dependent on NOTCH1/2 receptors in T cells and Dll1/4 ligands in the recipient, with dominant roles for NOTCH1 and Dll4 (29). NOTCH-inhibited T cells acquire a hyporesponsive phenotype in both CD4 and CD8 populations. NOTCH deprived T cells markedly reduced cytokine production but maintain their expansion capacity and their in vitro cytotoxic ability (30).
The exact mechanisms of NOTCH modulation in T cells remain to be elucidated. Mochizuki et al. (37) in murine model showed that during GvHD, inflammatory DCs Dll4 ligand positive produce significantly high level of IFN-γ and IL-17. More recently, Chung et al. (27) showed that NOTCH signal are delivered to donor T cells shortly after transplantation and that host stromal cells are the source for NOTCH ligands during in vivo priming of alloreactive T cells. Interestingly, Luo et al. (38) have shown in an MHC-mismatched murine all-BMT model, inhibition of NOTCH signaling reduce the incidence of GvHD by reducing DCs and CD8 T cell proliferation and activation.
NOTCH pathway inhibition could be therapeutically targeted by: (1) GSIs that block the proteolytic activation after the NOTCH/NOTCH ligand interaction (39). However, the use of GSIs in murine model of GvHD is associated with a severe toxicity in the gut epithelium (29); (2) monoclonal antibodies directed against NOTCH ligands such as Dll1–4 (29); (3) we recently identified the calcium channel modulator bepridil as a new NOTCH1 pathway inhibitor in Chronic Lymphocytic Leukemia (40). It represents an attractive therapeutic strategy to prevent also GvHD (Figure 1).
Figure 1. NOTCH signaling and graft-versus-host disease (GvHD). The effects of NOTCH signaling during GvHD are dependent on NOTCH1/2 receptors in T cells and Dll1/4 ligands in the recipient, with dominant roles for NOTCH1 and Dll4. Inhibition of canonical NOTCH signaling by γ-secretase inhibitor (GSI)-inhibitor, anti Dll1–4 antibodies, bepridil, and regulatory T cells (Tregs) markedly decreased GVHD (28–30). Tregs inhibit the NOTCH/NOTCH ligand interactions. They act through the CD39/adenosine axis to inhibit the NOTCH pathway which, in turn, regulates T cell proliferation and consequently inhibits GvHD. Blocking CD39/adenosine axis reverts NOTCH inhibition and favors GvHD onset (49).
Regulatory T Cells (Tregs) Downregulate NOTCH Signaling in Donor T Cells
Regulatory T cells suppressed alloimmune reactions like, for example, GvHD (41). They also promoted tolerance to allogeneic organ transplants (42). Adoptive Treg/conventional T cell (Tcons)-based immunotherapy in full-haplotype mismatched transplantation practically eliminated acute and cGvHD, supported post-transplant immunological reconstitution and exerted a strong GvL effect (43–48) in high-risk AL patients.
Although the mechanisms underlying Treg suppression of GvHD with no loss of GvL activity remain to be unraveled, the principal hypotheses are based on (a) the Treg/Tcon homing and distribution patterns and (b) different molecular pathways in Tcon activation and proliferation and, consequently, GvL and GvHD. Interestingly, using humanized antibodies and conditional genetic mouse models to inactivate NOTCH signaling in donor T cells markedly reduced GvHD severity and mortality (28–30). NOTCH signaling other than a cell autonomous mechanism can be modulated with an extrinsic signal from an adjacent interacting cell. Current evidence suggests that Tregs and anti-NOTCH1 compounds inhibit the same NOTCH ligands and receptors on Tcons (29, 49). Mimicking the drug-mediated NOTCH1 inhibition (30), Tregs directly inhibited NOTCH1 signaling on Tcons in vitro and in vivo, with the blockade being observed on CD4 and CD8 cells from mouse lymph nodes (49). Jagged1 and Dll4 NOTCH1 ligands, played major roles (49) with Dll4 being reported to mediate all NOTCH signaling effects in Tcons during GvHD (29). As a GvHD prevention strategy, using alloantigen-specific Tregs which preferentially inhibit alloreactive Tcons to downregulate NOTCH1 clearly offers advantages over administering pharmaceutical agents which exert a total blockade on NOTCH1 signaling on all Tcons.
CD39–NOTCH1 pathway crosstalk was also demonstrated (49). In fact, NOTCH1 expression and signaling on Tcons were restored when CD39 was blocked by the anti-CD39 monoclonal antibody or polyoxometalate-1 (POM-1), the selective CD39 inhibitor (49). Increased cAMP levels were associated with NOTCH1 reduction in Tcons; adding anti-CD39 reduced cAMP levels and reversed the Treg-mediated NOTCH1 reduction. GvHD reappeared in mice after POM-1 administration (49). In vitro studies (50–52) showed that blocking Abs or chemical products downmodulated the CD39/adenosine axis and reversed Treg suppression of T cons. Although the Treg mechanisms of action are multiple and partially unclear (53), these data showed that Tregs triggered NOTCH1 downregulation directly in Tcons and acted through the CD39/adenosine axis to inhibit the NOTCH pathway which, in turn, regulates Tcon proliferation (Figure 1). This mechanism of action could account for Treg-induced inhibition of Tcon proliferation which was observed by others (30).
Interestingly, in CD4 and CD8 cell populations, NOTCH1 downregulation was more marked in peripheral blood than in bone marrow (54). Tregs were demonstrated to block Tcons in the periphery but not in bone marrow (55). We could speculate that Treg homing patterns play a major role in these results. Tregs could have downregulated NOTCH1 expression in peripheral tissue because they homed there while, because of different migratory properties, they homed less efficiently, or not at all, to bone marrow. Translation of tissue-specific NOTCH1 expression into a strong GvL effect without GvHD, needs, however, to be elucidated in depth. A Treg-related NOTCH1 blockade could account for clinical and experimental evidence that Tregs prevented GvHD and facilitated a powerful Tcon-dependent GvL effect (44, 45). Consequently Treg-mediated NOTCH inhibition, like drug-induced NOTCH downregulation (28–30) may separate GvHD from GvL. This finding has major implications for adoptive immunotherapy strategies in the field of transplantation for leukemia.
Mesenchymal Stem Cells (MSCs) Recruit Induced Tregs (iTregs) by Activating NOTCH Signaling
NOTCH1 signaling is also involved in Treg cell differentiation. Liotta et al. had described Jagged1 involvement in MSC suppression of T-cell proliferation (56). Our group showed when cocultured with CD3+ cells, MSCs induced a T-cell population with a regulatory phenotype (57). When CD4+ T cells were cocultured with MSCs, the NOTCH1 pathway was found to be activated (58). Using GSI-I or the NOTCH1 neutralizing antibody to inhibit NOTCH1 signaling reduced HES1 expression (the NOTCH1 downstream target) and the percentage of MSC-induced CD4+CD25highFOXP3+ cells in vitro (58) (Figure 2). In human cells FOXP3 is another NOTCH signaling downstream target (58), thus data from murine models were extended (59). NOTCH signaling activation reversed the unstable regulatory/suppressive properties of iTreg cells, ensuring sustained FOXP3 expression and stable Treg-cell phenotypes (58). No crosstalk between NOTCH1 and TGF-β signaling pathways was observed (58). Previous studies had demonstrated TGF-β production was involved in MSCs-mediated Treg cell induction (60, 61) and reported TGF-β/NOTCH1 crosstalk (58) in peripheral Treg cell maintenance. Lack of T-cell receptor stimulation in the work by Del Papa et al. may account for the discrepancy with other reports (58, 62–64). Together, these findings indicated that NOTCH1 pathway activation played a role in MSC-mediated human Treg-cell induction. In conclusion while on one side our observation on MSC-T cell coculture suggest a positive role of NOTCH in the generation of iTregs, on the other side NOTCH inhibition (drug or Treg mediated) in mature donor T cells is associated with reduction in GvHD severity and mortality.
Figure 2. Mesenchymal stem cells (MSCs) recruit induced Tregs (iTregs) by activating Notch signaling. When cocultured with CD4+ cells, MSCs induced a T-cell population with a regulatory phenotype (iTregs) (57). NOTCH1 pathway is activated in CD4+ T cells cocultured with MSCs. Inhibition of NOTCH1 signaling through γ-secretase inhibitor (GSI)-I or the NOTCH1 neutralizing antibody reduced expression of HES1 and the percentage of MSC-induced CD4+CD25highFOXP3+ cells in vitro (58).
Conclusion and Perspectives
Allogeneic immune system played a crucial role not only in mediating the onset of GvHD but also in eradicating malignancy, i.e., the GvL effect. Separating GvHD from GvL represent a major challenge. GvHD prophylaxis and treatment is mainly based on immunosuppressive treatment with drugs such as cyclosporine, tacrolimus, methotrexate, antithymocyte globulin, and glucocorticoids (4). Data reviewed here showed NOTCH1 as a new major regulator of alloreactivity. Triggering NOTCH pathway with pharmacological (GSIs, Ab anti-Notch) or cellular (Tregs) ways might represent a new strategy to separate GvHD from GvL.
Author Contributions
MDI organized the plan and structure of the manuscript, and all the authors contributed to the redaction.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 12(6):443–58. doi:10.1038/nri3212
2. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic stem cell transplantation. J Clin Oncol (2011) 29(16):2230–9. doi:10.1200/JCO.2010.33.7212
3. Pidala J, Anasetti C. Glucorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant (2011) 16(11):1504–18. doi:10.1016/j.bbmt.2010.01.007
4. Zeiser R, Blazar BR. Acute graft-versus-host disease-biologic process, prevention, and therapy. N Engl J Med (2017) 377(22):2167–79. doi:10.1056/NEJMra1609337
5. Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol (2017) 8:79. doi:10.3389/fimmu.2017.00079
6. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood (2011) 117(12):3268–76. doi:10.1182/blood-2010-12-290403
7. Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med (2017) 377(26):2565–79. doi:10.1056/NEJMra1703472
8. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 16(12):1611–28. doi:10.1016/j.bbmt.2010.06.015
9. Weiden PL, Flournoy N, Thomas ED, Prenticee R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med (1979) 300:1068–10739. doi:10.1056/NEJM197905103001902
10. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood (1990) 75(3):555–62.
11. Kloosterman TC, Martens AC, van Bekkum DW, Hagenbeek A. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect. Bone Marrow Transplant (1995) 15(4):583–90.
12. Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature (1979) 281(5731):490–1. doi:10.1038/281490a0
13. Reddy P, Maeda Y, Liu C, Krijanovski OL, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 11(11):1244–9. doi:10.1038/nm1309
14. Rezvani K, Barrett AJ. Characterizing and optimizing immune response to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Hematol (2008) 21(3):437–53. doi:10.1016/j.beha.2008.07.004
15. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Galeet RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood (2010) 116(11):1839–48. doi:10.1182/blood-2010-04-278317
16. Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland HK, et al. T cell replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide. Results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol (2013) 31(10):1310–6. doi:10.1200/JCO.2012.44.3523
17. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood (2013) 121:752–8. doi:10.1182/blood-2012-08-449108
18. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo A, Cerretti R, et al. Haploidentical unmanipulated, G-CSF-primed bone marrow transplantation for patients with high risk hematological malignancies. Blood (2013) 121(5):849–57. doi:10.1182/blood-2012-08-453399
19. Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci (2013) 126(Pt10):2135–40. doi:10.1242/jcs.127308
20. Grazioli P, Felli MP, Screpanti I, Campese AF. The mazy case of Notch and immunoregulatory cells. J Leukoc Biol (2017) 102(2):361–8. doi:10.1189/jlb.1VMR1216-505R
21. Toubai T, Tawara I, Sun Y, Liu C, Nieves E, Evers R, et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2012) 119(16):3844–53. doi:10.1182/blood-2011-10-384057
22. Li H, Demetris AJ, McNiff J, Matte-Martone C, Tan HS, Rothstein DM, et al. Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 188(8):3804–11. doi:10.4049/jimmunol.1102795
23. Radtke F, Fasnacht N, MacDonald HR. Notch signaling in the immune system. Immunity (2010) 32:14–27. doi:10.1016/j.immuni.2010.01.004
24. Osborne BA, Minter LM. Notch signalling during peripheral T-cell activation and differentiation. Nat Rev Immunol (2007) 7:64–75. doi:10.1038/nri1998
25. Amsen D, Antov A, Flavell RA. The different faces of Notch in t-helper differentiation. Nat Rev Immunol (2009) 9:116–24. doi:10.1038/nri2488
26. Backer RA, Helbig C, Gentek R, Kent A, Laidlaw BJ, Dominguez CX, et al. A central role for Notch in effector CD8+ T cell differentiation. Nat Immunol (2014) 15:1143–51. doi:10.1038/ni.3027
27. Chung J, Ebens CL, Perkey E, Radojcic V, Koch U, Scarpellino L, et al. Fibroblasic niche prime T cell alloimmunity through delta-like Notch ligands. J Clin Invest (2017) 127(4):1574–88. doi:10.1172/JCI89535
28. Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT, et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2011) 117(1):299–308. doi:10.1182/blood-2010-03-271940
29. Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT, et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 123(4):1590–604. doi:10.1172/JCI65477
30. Sandy AR, Chung J, Toubai T, Shan GT, Tran YT, Friedman A, et al. T cell-specific Notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD$+ and CD8+ T cells. J Immunol (2013) 190(11):5818–28. doi:10.4049/jimmunol.1203452
31. Charbonnier LM, Wang S, Georgiev P, Sefik E, Chatila TA. Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat Immunol (2015) 16(11):1162–73. doi:10.1038/ni.3288
32. Santos e Sousa P, Cirè S, Conlan T, Jardine L, Tkacz C, Ferrer IR, et al. Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease. JCI Insight (2018) 3(5):e97011. doi:10.1172/jci.insight.97011
33. Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GvHD. Blood (2017) 130:2131–45. doi:10.1182/blood-2017-05-782466
34. Roderick JE, Gozalez-Perez G, Kuksin CA, Dongre A, Roberts ER, Srinivasan J, et al. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med (2013) 210:1311–29. doi:10.1084/jem.20112615
35. Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S, et al. Trascriptome analysis of GvHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med (2016) 7:315ra191. doi:10.1126/scitranslmed.aad3231
36. Perkey E, Maillard I. New insights into graft-versus-host disease and graft rejection. Annu Rev Pathol (2018) 13:219–45. doi:10.1146/annurev-pathol-020117-043720
37. Mochizuki K, Xie F, He S, Tong Q, Liu Y, Mochizuki I, et al. Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol (2013) 190:3772–82. doi:10.4049/jimmunol.1202820
38. Luo X, Xu L, Li Y, Tan H. Notch pathway plays a novel and critical role in regulating responses of T and antigen presenting cells in GvHD. Cell Biol Toxicol (2017) 33:169–81. doi:10.1007/s10565-016-9364-7
39. Wolfe MS. γ-secretase in biology and medicine. Semin Cell Dev Biol (2009) 20:219–24. doi:10.1016/j.semcdb.2008.12.011
40. Baldoni S, Del Papa B, Dorillo E, Aureli P, De Falco F, Rompietti C, et al. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. Int J Cancer (2018) 143(4):958–70. doi:10.1002/ijc.31355
41. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 9:1144–50. doi:10.1038/nm915
42. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 22:531–62. doi:10.1146/annurev.immunol.21.120601.141122
43. Di Ianni M, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Cantelmi MG, et al. T regulatory cell separation for clinical application. Transfus Apher Sci (2012) 47(2):213–6. doi:10.1016/j.transci.2012.06.007
44. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 117(14):3921–8. doi:10.1182/blood-2010-10-311894
45. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, et al. HLA-haploidentical transplantation with regulatory and conventional T cell adoptive immunotherapy prevents acute leukemia relapse. Blood (2014) 124(4):638–44. doi:10.1182/blood-2014-03-564401
46. Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, et al. “Designed” grafts for HLA-haploidentical stem cell transplantation. Blood (2014) 123:967–73. doi:10.1182/blood-2013-10-531764
47. Lussana F, Di Ianni M, Rambaldi A. Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant (2017) 52:1225–32. doi:10.1038/bmt.2017.30
48. Del Papa B, Ruggeri L, Urbani E, Baldoni S, Cecchini D, Zei T, et al. Clinical-grade-expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell dependent graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant (2017) 23(11):1847–51. doi:10.1016/j.bbmt.2017.07.009
49. Del Papa B, Pierini A, Sportoletti P, Baldoni S, Cecchini D, Rosati E, et al. The NOTCH1/CD39 axis: a Treg trip-switch for GvHD. Leukemia (2016) 30(9):1931–4. doi:10.1038/leu.2016.87
50. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 7:e1002110. doi:10.1371/journal.ppat.1002110
51. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods (2011) 369(1–2):59–68. doi:10.1016/j.jim.2011.04.004
52. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE, et al. CD39/ENTPD1 expression by CD4+FoxP3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 139(3):1030–40. doi:10.1053/j.gastro.2010.05.007
53. Caridade M, Graca L, Ribeiro RM. Mechanisms underlying CD4+ Treg immune regulation in the adult: from experiments to models. Front Immunol (2013) 18(4):378. doi:10.3389/fimmu.2013.00378
54. Di Ianni M, Olioso P, Giancola R, Santarone S, Natale A, Papalinetti G, et al. Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT. Int J Hematol (2017) 106(6):860–4. doi:10.1007/s12185-017-2292-3
55. Ruggeri L, Di Ianni M, Urbani E, Mancusi A, Falzetti F, Carotti A, et al. Tregs suppress GvHD at the periphery and unleash the Gvl effect in the bone marrow. Blood (2014) 124(21):842.
56. Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2008) 26(1):279–89. doi:10.1634/stemcells.2007-0454
57. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol (2008) 36(3):309–18. doi:10.1016/j.exphem.2007.11.007
58. Del Papa B, Sportoletti P, Cecchini D, Rosati E, Balucani C, Baldoni S, et al. Notch1 modulates MSC-mediated regulatory T cell induction. Eur J Immunol (2013) 43(1):182–7. doi:10.1002/eji.201242643
59. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, et al. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood (2008) 112(5):1813–21. doi:10.1182/blood-2008-03-144980
60. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 156(1):149–60. doi:10.1111/j.1365-2249.2009.03874.x
61. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 198(12):1875–86. doi:10.1084/jem.20030152
62. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol (2001) 166(12):7282–9. doi:10.4049/jimmunol.166.12.7282
63. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGFbeta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J Immunol (2004) 172(9):5149–53. doi:10.4049/jimmunol.172.9.5149
Keywords: NOTCH, graft-versus-host disease, tolerance, graft-versus-leukemia, HSCT
Citation: Di Ianni M, Del Papa B, Baldoni S, Di Tommaso A, Fabi B, Rosati E, Natale A, Santarone S, Olioso P, Papalinetti G, Giancola R, Accorsi P, Di Bartolomeo P, Sportoletti P and Falzetti F (2018) NOTCH and Graft-Versus-Host Disease. Front. Immunol. 9:1825. doi: 10.3389/fimmu.2018.01825
Received: 30 March 2018; Accepted: 24 July 2018;
Published: 10 August 2018
Edited by:
Barbara A. Osborne, University of Massachusetts Amherst, United StatesReviewed by:
Ivan Maillard, University of Pennsylvania, United StatesStefanie Sarantopoulos, Duke University, United States
Ronjon Chakraverty, University College London, United Kingdom
Copyright: © 2018 Di Ianni, Del Papa, Baldoni, Di Tommaso, Fabi, Rosati, Natale, Santarone, Olioso, Papalinetti, Giancola, Accorsi, Di Bartolomeo, Sportoletti and Falzetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mauro Di Ianni, bWF1cm8uZGlpYW5uaSYjeDAwMDQwO3VuaWNoLml0
†These authors have contributed equally to this work.